Battling Kidney Disease: This Biotech Company Achieves Major Milestone

FDA Approves XPHOZAH® (tenapanor), a Significant Milestone in Chronic Kidney Disease Treatment

FDA Approves XPHOZAH® (tenapanor), a Significant Milestone in Chronic Kidney Disease Treatment

The U.S. Food and Drug Administration (FDA) has granted approval to XPHOZAH® (tenapanor), marking a significant breakthrough in the treatment of chronic kidney disease (CKD). Developed by Ardelyx Inc., a specialized biopharmaceutical company, XPHOZAH® is a firs…